World's Best Scientists 2026 revealed!
Award Badge
Medicine
Italy
2023

D-Index & Metrics

Medicine

D-Index
147
Citations
99625
World Ranking
1262
National Ranking
28

Research.com Recognitions

  • 2023 - Research.com Medicine in Italy Leader Award

Overview

Aron Goldhirsch was affiliated with the European Institute of Oncology in Italy. Their research primarily focused on medicine with a significant emphasis on oncology and cancer research. Their work contributed to multiple subfields including oncology, cancer research, pulmonary and respiratory medicine, genetics, and public health, environmental, and occupational health.

The scientist's main topics of investigation included:

  • Advanced Breast Cancer Therapies
  • Breast Cancer Treatment Studies
  • Estrogen and related hormone effects
  • Cancer Risks and Factors
  • Reproductive Biology and Fertility
  • Cancer survivorship and care
  • Cancer Genomics and Diagnostics

Among their recent published papers were:

  • "Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer," 2023, New England Journal of Medicine
  • "Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials," 2022, Journal of Clinical Oncology
  • "Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion," 2021, Clinical Cancer Research
  • "Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D," 2022, The Breast
  • "Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy," 2021, The Breast

Goldhirsch published frequently in specific scientific venues including:

  • The Breast
  • Cancer Research
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Clinical Cancer Research

Collaborations were a notable part of their academic output. Frequent co-authors included:

  • Marco Colleoni
  • Richard D. Gelber
  • Olivia Pagani
  • Meredith M. Regan
  • Alan S. Coates

This body of work indicates a sustained engagement with breast cancer studies, focusing on treatment strategies, genetic factors influencing cancer diagnosis, hormone-related effects, and survivorship care.

Best Publications

  • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

    Martine J. Piccart-Gebhart;Marion Procter;Brian Leyland-Jones;Aron Goldhirsch

  • Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

    A. Goldhirsch;W.C. Wood;A.S. Coates;R.D. Gelber

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

    Beat Thürlimann;Aparna Keshaviah;Alan S Coates

  • Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

    A. S. Coates;E. P. Winer;A. Goldhirsch;R. D. Gelber

  • 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

    Ian Smith;Marion Procter;Richard D Gelber;Sébastien Guillaume

  • Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

    Aron Goldhirsch;J. N. Ingle;R. D. Gelber;A. S. Coates

  • Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

    José Baselga;José Baselga;Ian Bradbury;Holger Eidtmann;Serena Di Cosimo;Serena Di Cosimo

  • Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005

    A. Goldhirsch;J. H. Glick;R. D. Gelber;A. S. Coates

  • Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial

    Viviana Galimberti;Bernard F. Cole;Bernard F. Cole;Stefano Zurrida;Giuseppe Viale;Giuseppe Viale

  • Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007

    A. Goldhirsch;W. C. Wood;R. D. Gelber;A. S. Coates

  • Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

    Alan S. Coates;Aparna Keshaviah;Beat Thürlimann;Henning Mouridsen

  • Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

    B A Gusterson;R D Gelber;A Goldhirsch;K N Price

  • Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer

    Aron Goldhirsch;John H. Glick;Richard D. Gelber;Hans-Jörg Senn

  • 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

    David Cameron;Martine J Piccart-Gebhart;Richard D Gelber;Richard D Gelber;Marion Procter

  • Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer

    Aron Goldhirsch;William C. Wood;Richard D. Gelber;Alan S. Coates

  • Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines

    G. Curigliano;D. Cardinale;T. Suter;G. Plataniotis

  • Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer

    Aron Goldhirsch;John H. Glick;Richard D. Gelber;Alan S. Coates

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

  • Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update

    Manfred Kaufmann;Gabriel N. Hortobagyi;Aron Goldhirsch;Suzy Scholl

Frequent Co-Authors

Richard D. Gelber
Richard D. Gelber Harvard University
Giuseppe Viale
Giuseppe Viale University of Milan
Marco Colleoni
Marco Colleoni European Institute of Oncology
Alan S. Coates
Alan S. Coates University of Sydney
Karen N. Price
Karen N. Price Frontier Science Foundation
Vincenzo Bagnardi
Vincenzo Bagnardi University of Milano-Bicocca
Paolo Veronesi
Paolo Veronesi European Institute of Oncology
Meredith M. Regan
Meredith M. Regan Harvard University
Giuseppe Curigliano
Giuseppe Curigliano University of Milan
Nicole Rotmensz
Nicole Rotmensz European Institute of Oncology

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare careers outside of the traditional medicine route, there are several flexible online pathways to consider. Programs such as direct entry msn programs for non-nurses online offer a fast-track for individuals with a non-nursing background to enter advanced nursing fields. These programs are designed for career changers and typically emphasize a streamlined curriculum.

If you’re seeking nursing schools with more accessible admission criteria, a number of easy nursing programs to get into can help you start your journey in the healthcare sector. Many schools also offer LPN programs with no entrance exam requirements; you can learn more about these options at lpn program no entrance exam.

If you’re looking for administrative roles in healthcare, consider training at medical billing and coding schools that accept financial aid. These programs prepare you for essential support roles in medical offices and hospitals, with flexible online learning and financial support options.

Best Scientists Citing Aron Goldhirsch

Recently Published Articles